The clinical relevance of this compound metabolizer phenotype is highlighted in a study on Brazilian patients with ALL, which found that 0.9% of the cohort were heterozygous carriers for both NUDT15 and TPMT non-function alleles. This evidence concerns the gene TPMT and acute lymphoblastic leukemia.